Quarterly report · Q1

Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥74.7bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥299.4bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥71.9bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥892m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥936m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥913m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥6.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥993m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥925m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥993m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥391m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥427m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥391m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥427m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥195.3bnat 2022-06-30Cons.Assets
Total assets¥178.8bnat 2022-03-31Cons.Assets
Total assets¥199.1bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥142.4bnat 2022-06-30Cons.Liabilities
Total liabilities¥125.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥52.9bnat 2022-06-30Cons.Net assets
Net assets / equity¥52.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥49.9bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥31.5bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥25.5bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥13.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥123.562021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.272021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio27.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio25.1%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥1.8bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥355m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥6.3bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥270m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥78.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥74.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥1.7bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥278m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥12.2bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥7.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥451m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥77.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥71.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 352
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任監査法人トーマツ
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)桃木 秀一 
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)佐野 明宏
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration71851000000JPY
Net sales (5-year summary)CurrentYTDDuration74709000000JPY
Net sales (5-year summary)Prior1YearDuration299392000000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration993000000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration913000000JPY
Ordinary income loss (5-year summary)Prior1YearDuration6767000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration427000000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration391000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration3705000000JPY
Comprehensive income (5-year summary)Prior1YTDDuration433000000JPY
Comprehensive income (5-year summary)CurrentYTDDuration395000000JPY
Comprehensive income (5-year summary)Prior1YearDuration3758000000JPY
Net assets (5-year summary)Prior1QuarterInstant49926000000JPY
Net assets (5-year summary)CurrentQuarterInstant52897000000JPY
Net assets (5-year summary)Prior1YearInstant52876000000JPY
Total assets (5-year summary)Prior1QuarterInstant199050000000JPY
Total assets (5-year summary)CurrentQuarterInstant195341000000JPY
Total assets (5-year summary)Prior1YearInstant178753000000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration14.27
Basic earnings loss per share (5-year summary)CurrentYTDDuration13.05
Basic earnings loss per share (5-year summary)Prior1YearDuration123.56
Diluted earnings per share (5-year summary)Prior1YTDDuration-
Diluted earnings per share (5-year summary)CurrentYTDDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.2508
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.2708
Equity to asset ratio (5-year summary)Prior1YearInstant0.2958
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember32048000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember32048000
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant32048000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant32048000
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember2061100
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember29920600
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember299206
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember66300
Number of shares issued shares voting rightsCurrentQuarterInstant32048000
Number of voting rights issued shares voting rightsCurrentQuarterInstant299206
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member2061100
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member2061100
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0643

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass